Dr. Gail J.Roboz

Top hematologist oncologist specializing in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).

About

Dr. Gail J. Roboz, MD, is a leading authority in hematologic malignancies, specializing in the diagnosis and treatment of leukemia and related blood disorders. She is a Professor of Medicine at Weill Cornell Medical College and serves as the Director of the Clinical and Translational Leukemia Program at the Weill Cornell Medicine Meyer Cancer Center and NewYork-Presbyterian Hospital. Dr. Roboz earned her medical degree from Mount Sinai School of Medicine, completed her residency at NewYork-Presbyterian Hospital/Weill Cornell, and received fellowship training in hematology and medical oncology. Board-certified in internal medicine, hematology, and medical oncology, she provides personalized care to patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and other complex blood cancers.

Why they are a top doctor

Research papers · PubMed

203

Published, peer-reviewed work, the clearest public measure of expertise in a specialty.

Cited by other doctors

26.5k

How often other doctors and researchers build on their work.

Background

Education

Medical school: Mount Sinai School of Medicine

Residency: Internal Medicine, New York Presbyterian Hospital

Fellowship: Hematology/Oncology, New York Presbyterian Hospital

Board certifications: Internal Medicine · Hematology · Medical Oncology

Areas of focus

Leukemia

Myelodysplastic Syndromes (MDS)

Awards

Summa cum laude, Yale University

Alpha Omega Alpha Medical Honor Society

Harold Elster Memorial Prize for Highest Academic Standing in the Graduating Class

American Society of Hematology Travel Award

The Lupin Foundation, Research Grant Awards

Weill Cornell Physician Organization "We Care" Award

Research Grant Award, Myeloproliferative Disorders Foundation

Research Grant Award, Katherine John Murphy Foundation

Memberships and affiliations

Weill Cornell Medical College

NewYork-Presbyterian Hospital

Editorial Boards of Blood, Journal of Clinical Oncology, and Cancer

Consultant to AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Pfizer, Roche, Janssen, Jazz Pharmaceuticals, Novartis

American Society of Hematology

American Society of Clinical Oncology

Selected publications

Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.

Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms.

A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.

High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemia.

Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia.

Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.

Transplant Outcomes in Myelofibrosis: Impact of Donor Type [Cord Blood Grafts Supported by CD34+ selected Cells (Haplo-Cord) vs Matched Donors].

Titles as indexed on PubMed.